No connection

Search Results

AGIO vs ANIP

AGIO
Agios Pharmaceuticals, Inc.
BEARISH
Price
$27.85
Market Cap
$1.63B
Sector
Healthcare
AI Confidence
85%
ANIP
ANI Pharmaceuticals, Inc.
BEARISH
Price
$70.49
Market Cap
$1.58B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AGIO
--
ANIP
21.23
Forward P/E
AGIO
-5.74
ANIP
6.82
P/B Ratio
AGIO
1.36
ANIP
2.73
P/S Ratio
AGIO
30.2
ANIP
1.79
EV/EBITDA
AGIO
-1.75
ANIP
10.33

Profitability

Gross Margin
AGIO
0.0%
ANIP
61.36%
Operating Margin
AGIO
-608.89%
ANIP
11.99%
Profit Margin
AGIO
0.0%
ANIP
8.87%
ROE
AGIO
-30.2%
ANIP
16.16%
ROA
AGIO
-19.93%
ANIP
3.82%

Growth

Revenue Growth
AGIO
86.1%
ANIP
29.6%
Earnings Growth
AGIO
--
ANIP
--

Financial Health

Debt/Equity
AGIO
0.03
ANIP
1.16
Current Ratio
AGIO
11.46
ANIP
2.71
Quick Ratio
AGIO
10.53
ANIP
2.07

Dividends

Dividend Yield
AGIO
--
ANIP
--
Payout Ratio
AGIO
0.0%
ANIP
0.0%

AI Verdict

AGIO BEARISH

AGIO's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates poor operational and financial health, while the absence of an Altman Z-Score raises red flags for potential bankruptcy risk. Despite strong revenue growth of 86.1% YoY, the company reports a 0.00% profit margin, negative operating margin of -608.89%, and negative ROE of -30.20%, signaling deep operational inefficiencies. Insider selling activity totaling $2.06M over six months, with multiple officer sales, underscores lack of confidence from within the organization. The stock trades at a premium valuation (Price/Sales of 30.20) with no earnings or cash flow support, and its 52-week high is 65% above current levels, indicating overvaluation relative to fundamentals.

Strengths
Strong revenue growth of 86.1% YoY, indicating market traction and product demand
High analyst consensus with a 'buy' recommendation from 8 analysts
Extremely low debt/equity ratio of 0.03, suggesting minimal leverage risk
Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and weak operational performance
Negative operating margin (-608.89%) and zero profit margin reflect unsustainable business model
Insider selling of 35,569 shares ($2.06M value) signals internal skepticism
ANIP BEARISH

ANIP's Piotroski F-Score of 4/9 indicates weak financial health, falling short of the stable threshold and signaling potential operational inefficiencies. The absence of an Altman Z-Score raises concern about bankruptcy risk, especially given a high debt/equity ratio of 1.16. Despite strong revenue growth (29.6% YoY) and solid gross margins (61.36%), the stock trades at a premium to its intrinsic value, with a current price of $70.49 versus a Graham Number of $43.90 and intrinsic value of $23.24. Insider selling activity totaling $3.39M in the last six months further undermines confidence, while technical trends remain bearish. Analysts remain optimistic with a $110.62 target, but this may reflect overvaluation given the underlying financial and sentiment risks.

Strengths
Strong revenue growth of 29.6% YoY
High gross margin of 61.36%
Solid operating margin of 11.99%
Risks
Piotroski F-Score of 4/9 indicates weak financial health
No Altman Z-Score available, raising potential bankruptcy risk
Insider selling activity totaling $3.39M in last 6 months

Compare Another Pair

AGIO vs ANIP: Head-to-Head Comparison

This page compares Agios Pharmaceuticals, Inc. (AGIO) and ANI Pharmaceuticals, Inc. (ANIP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile